Investor AB Has $13,163,000 Stake in Agile Therapeutics, Inc. (AGRX)
Investor AB maintained its position in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,510,189 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Agile Therapeutics comprises approximately 0.9% of Investor AB’s portfolio, making the stock its 2nd largest holding. Investor AB owned 12.19% of Agile Therapeutics worth $13,163,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Janney Montgomery Scott LLC purchased a new position in shares of Agile Therapeutics during the 2nd quarter valued at $122,000. Franklin Resources Inc. lifted its stake in shares of Agile Therapeutics by 39.2% in the 2nd quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after purchasing an additional 780,578 shares during the last quarter. Royce & Associates LP lifted its stake in shares of Agile Therapeutics by 206.1% in the 1st quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock valued at $3,165,000 after purchasing an additional 665,000 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Agile Therapeutics by 608.0% in the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,907 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Agile Therapeutics in the 2nd quarter valued at $309,000. Institutional investors and hedge funds own 67.59% of the company’s stock.
Several research firms recently issued reports on AGRX. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Agile Therapeutics in a research note on Friday, July 21st. Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a research note on Sunday, July 30th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Agile Therapeutics in a research note on Monday. Royal Bank Of Canada set a $8.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a research note on Sunday, July 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price objective on shares of Agile Therapeutics in a research note on Thursday, September 21st. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Agile Therapeutics presently has an average rating of “Buy” and a consensus price target of $10.20.
Agile Therapeutics, Inc. (AGRX) traded up 4.95% during midday trading on Thursday, hitting $5.09. 355,477 shares of the company traded hands. Agile Therapeutics, Inc. has a 12-month low of $1.82 and a 12-month high of $7.95. The firm’s market capitalization is $146.62 million. The stock’s 50-day moving average is $3.71 and its 200-day moving average is $3.63.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. During the same quarter in the prior year, the company posted ($0.29) earnings per share. Analysts anticipate that Agile Therapeutics, Inc. will post ($1.02) EPS for the current fiscal year.
In other Agile Therapeutics news, Chairman Alfred Altomari bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The stock was acquired at an average price of $3.34 per share, with a total value of $33,400.00. Following the completion of the transaction, the chairman now owns 161,587 shares in the company, valued at $539,700.58. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.50% of the stock is currently owned by company insiders.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.